Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03393884 · ClinicalTrials.gov registry record · Phase 1
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
A Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by Imunon.
- Active
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT03393884 is a Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that is active but no longer recruiting, run by Imunon. The registered enrollment target is 130 participants, below the 254-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT03393884, a Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, is active but no longer recruiting, sponsored by Imunon.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL IMNN-001
Study Locations (20)
New York
- Monter Cancer Center - Lake Success
- NYU Langone, Long Island - Mineola
- NYU Langone - New York
Alabama
- University of Alabama Birmingham - Birmingham
- Mitchell Cancer Institute (University of South Alabama) - Mobile
California
- Gynecologic Oncology Associates (Hoag Hospital) - Newport Beach
- Innovative Clinical Research - Whittier
Florida
- Advent Health - Orlando
- Women's Care Florida - St. Petersburg
New Jersey
- MD Anderson at Cooper - Camden
- Hackensack University Medical Center - Hackensack
Tennessee
- Chattanooga Women's Health - Chattanooga
- The West Clinic - Germantown
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2018-09-05 |
| Est. Completion | 2026-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03393884
The ClinicalTrials.gov registry entry for NCT03393884 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 254-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (49% lower). The listed sponsor is Imunon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT03393884 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03393884 about?
NCT03393884 is a clinical study titled "Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)". This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
What is the current status of trial NCT03393884?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2018-09-05. Estimated completion is 2026-03-30.
What conditions does trial NCT03393884 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cancer.
What interventions are being tested in trial NCT03393884?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), IMNN-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03393884?
This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03393884 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 1
-
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
RECRUITING · Phase 1
-
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RECRUITING · Phase 1
-
A Study of ZN-c3 in Patients With Ovarian Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.